REMODELING OF AN ENDOCERVICAL STEM CELL NICHE IN HPV-ASSOCIATED PRECANCER AND MICROINVASIVE CANCER OF THE CERVIX UTERI


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To study the morphological manifestations of and the molecular mechanisms for remodeling of an endocervical stem cell niche (ESCN) in human papillomavirus (HPV)-associated precancer and microinvasive cancer of the cervix uteri (CCU). Materials and methods. Retrospective clinicomorphological and molecular biological studies were conducted using cytological, biopsy, and intraoperative specimens from 251 patients with various HPV-associated abnormalities of the cervix uteri: flat condyloma (n=80), CIN I (n=47), CIN II-III (n=110), and microinvasive carcinoma (n=14). Immunocytochemical and immunohistochemical studies were performed. The markers р16INK4a, Ki-67, СХ17, Oct-4, SMA, CD34, MMP2, and Vimentin were determined. Real-time polymerase chain reaction (PCR) and in situ PCR were carried out to identify 14 high-risk HPV types in 79 women. Results. HPV infection causes ESCN remodeling, giving rise to abnormal epithelial repair, precancer and cancer of the cervix uteri. A key role in these processes is played by viral integration with tissue epithelial stem cells and decompensated progenetic mesenchymal cell function. The development of flat CCU is accompanied by the emergence of cancer cell clones with the signs of stemness. Conclusion. Comprehensive female examination comprising cytology with HPV testing and evaluation of the status of ESCN should be recommended to improve the early diagnosis and prevention of CCU.

Full Text

Restricted Access

About the authors

E. A KOGAN

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: koganevg@gmail.com

N. M FAIZULLINA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: nafisa05@inbox.ru

S. A DEMURA

I.M. Sechenov First Moscow State Medical University

Email: sophja_demoura@mail.ru

T. A DEMURA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: demura-t@yandex.ru

A. Kh ISRAILOVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: angel_55@list.ru

A. V KOZACHENKO

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: a_kozachenko@oparina4.ru

References

  1. Новик В.И. Скрининг рака шейки матки. Практическая онкология. 2010; 11(2): 66—73.
  2. Polak J., ed. Cell therapy for lung disease. Imperial College London, UK; 2010. 504.
  3. Anttila A., Kotaniemi-Talonen L., Leinonen M., Hakama M., Laurila P., Tarkkanen J. et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage:randomised study within organised screening programme. Br. Med. J. 2010; 340: 1804.
  4. Baege A., Schlegel R., Baker C. Identification and isolation of putative cervical stem cells based on cell surface phenotype. In: 8th International conference on malignancies in AIDS and other immunodeficiencies. April 29—30, 2004. Bethesda, Maryland: Natcher Conference Center; 2004: 36.
  5. Castle P.E., Stoler M.H., Wright T.C. Jr., Sharma A., Wright T.L., Behrens C.M. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011; 12 (9): 880—90.
  6. Dean M. Cancer stem cells: redefining the paradigm of cancer treatment strategies. Mol. Interv. 2006; 6 (3): 140 Новик В.И. Скрининг рака шейки матки. Практическая онкология. 2010; 11(2): 66—73.
  7. Polak J., ed. Cell therapy for lung disease. Imperial College London, UK; 2010. 504.
  8. Anttila A., Kotaniemi-Talonen L., Leinonen M., Hakama M., Laurila P., Tarkkanen J. et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage:randomised study within organised screening programme. Br. Med. J. 2010; 340: 1804.
  9. Baege A., Schlegel R., Baker C. Identification and isolation of putative cervical stem cells based on cell surface phenotype. In: 8th International conference on malignancies in AIDS and other immunodeficiencies. April 29-30, 2004. Bethesda, Maryland: Natcher Conference Center; 2004: 36.
  10. Castle P.E., Stoler M.H., Wright T.C. Jr., Sharma A., Wright T.L., Behrens C.M. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011; 12 (9): 880—90.
  11. Dean M. Cancer stem cells: redefining the paradigm of cancer treatment strategies. Mol. Interv. 2006; 6 (3): 140—8.
  12. Dillner J., Rebolj M., Birembaut Ph., Petry K.U., Szarewski A., Munk C. et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. Br. Med. J. 2008; 337: 1754.
  13. Kines R.C., Thompson C.D., Lowy D.R., Schiller J.T., Day P.M. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc. Natl. Acad. Sci. USA. 2009; 106(48): 20458—63.
  14. Martens J.E., Arends J., Van der Linden P.J., De Boer B.A., Helmerhorst T.J. Cytokeratin 17 and p63 are markers of the HPV target cell, the cervical stem cell. Anticancer Res. 2004; 24(2B): 771—5.
  15. Mutter G.L., Prat J., eds. Robboy’s pathology of the female reproductive tract. 2nd ed. London: Churchill Livingstone Elsevier; 2009: 173—296.
  16. Wright T.C Jr., Massad S.L., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D. 2006 consensus guidelines for the management of woman with abnormal cervical screening tests. Am. J. Obstet. Gynecol. 2007; 197 (4): 346—55.
  17. Zvaifler N.J. Relevance of the stroma and epithelialmesenchymal transition (EMT) for the rheumatic diseases. Arthr. Res. Ther. 2006; 8 (3): 210.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies